Skip to main content
Caplight Logo









Phlox Therapeutics

Phlox Therapeutics

Private
NaardenHealthcare & Life Scienceshttps://phloxtherapeutics.com/

Last Round

Seed

Nov 6, 2024

Total Funding Raised

$2.03M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Phlox Therapeutics is a biotechnology company that develops first-in-class RNA therapies for rare genetic cardiomyopathies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

gene therapyRNA therapeuticscardiomyopathylaminopathygenetic medicineprecision medicineheart failure treatmentbiotech startuppreclinical researchdrug discoveryrare disease therapygenetic heart diseasebiotech R&Dgenomics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Phlox Therapeutics Comparables

Compare Phlox Therapeutics with similar companies based on industry and business-model similarity.

Phlox Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nuevocor
81%
Bayer AG
73%
BioMarin Pharmaceutical Inc.
73%

Phlox Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedNov 6, 2024
SeedMay 9, 2023
Pre SeedMay 16, 2022

Key People

Founding team and executive leadership

Margien Boels

Chief Operating Officer

Executive Team

Phlox Therapeutics Investors

Notable investors and investment history

Phlox Therapeutics investors
InvestorRounds
ROM Utrecht RegionSeed
Amsterdam UMC Ventures HoldingSeed
Innovation Fund Noord-HollandSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 38% MoM.

  • May 14, 2026

    Monthly visitors grew 71% MoM, reaching 1.2K.

Phlox Therapeutics Filings

Explore SEC and related filing metadata, where available.

Phlox Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Phlox Therapeutics's valuation, stock price, and market status.

Is Phlox Therapeutics a public or private company?

Phlox Therapeutics is a private company.

What is the current stock price of Phlox Therapeutics?

Phlox Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Phlox Therapeutics worth (valuation)?

Valuation information for Phlox Therapeutics is not publicly available.

Can I buy Phlox Therapeutics stock?

Phlox Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Phlox Therapeutics's last funding round?

Phlox Therapeutics's most recent funding round was Seed on November 6, 2024.

Who are the main investors in Phlox Therapeutics?

Key investors in Phlox Therapeutics include ROM Utrecht Region, Amsterdam UMC Ventures Holding, Innovation Fund Noord-Holland.

Will Phlox Therapeutics IPO soon?

No public IPO plans have been announced for Phlox Therapeutics.

How can I track Phlox Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Phlox Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNaarden
Employee Range7
Year Founded2022
Last FundingNov 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?